Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Dietary Supplement Division Soon May Need Office Accommodations

This article was originally published in The Tan Sheet

Executive Summary

Without an objection from Congress, FDA’s Division of Dietary Supplement Programs becomes a CFSAN office on Dec. 21. Objections or questions from one or more members are possible, but HHS likely would not make the notification without high confidence Congress would not object.

You may also be interested in...



Welch Leads US FDA’s Dietary Supplement Office

Center for Food Safety and Applied Nutrition says Cara Welch selected to fill Office of Dietary Supplement Programs director post. She’ll move up from ODSP deputy director on 14 March.

US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators

Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.

Next US FDA Commissioner Will Have Opening To Fill In Dietary Supplement Programs Office

Steven Tave on 15 March will move from ODSP director to lead ORA’s Office of Strategic Planning and Operational Policy. Agency’s next commissioner, who Capitol Hill lobbyists say could be named next week, will appoint a replacement.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS108058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel